Ocular Therapeutix Inc (OCUL) FinancialsOCULOcular Therapeutix Inc

Evaluating the bottom line, Ocular Therapeutix, Inc. maintains a gross margin of 85.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -609.34%, while the net margin is -584.51%. These profitability ratios, combined with a Return on Equity (ROE) of -72.99%, provide a clear picture of how effectively OCUL converts its operational activities into shareholder value.

In the context of the broader market, OCUL competes directly with industry leaders such as ETON and PAHC. With a market capitalization of $1.51B, it holds a significant position in the sector. When comparing efficiency, OCUL's gross margin of 85.08% stands against ETON's 67.61% and PAHC's 33.33%. Such benchmarking helps identify whether Ocular Therapeutix, Inc. is trading at a premium or discount relative to its financial performance.

The company's financial performance shows a troubling trend with negative net income reported at -$88,612,000 for Q1 2026 and a gross margin of 85.08%.